ANSO助力中科院高福院士团队研发的新冠病毒重组蛋白亚单位疫苗在乌兹别克斯坦上市
3月2日，乌兹别克斯坦创新发展部表示，乌政府已批准由中科院微生物所高福院士团队与安徽智飞龙科马生物制药有限公司联合研发的新冠病毒重组蛋白亚单位疫苗（ZF-UZ-VAC2001）投入使用，本月开始实施自愿接种。乌国评价该疫苗为世界上最安全，最有效的疫苗之一。
“一带一路”国际科学组织联盟（ANSO）在这一过程中发挥了至关重要的桥梁作用。鉴于国内疫情得到有效控制，在境外国家开展III期临床试验成为必由之路。ANSO秘书处积极牵线搭桥，推动该疫苗在境外开展III期临床试验，特别是在乌兹别克斯坦的试验合作。自2020年8月起，ANSO秘书处联络20多家国际合作机构和伙伴，包括政府部门、大学和科研机构，就推动该疫苗III期临床试验举办20余场视频会议。在ANSO的直接促成下，该疫苗于2020年12月6日正式在乌兹别克斯坦启动III期临床试验。7000名受试者参与试验，结果表明该疫苗具有很好的有效性和安全性，成果将于近期发表。III期 临床试验的顺利实施为该疫苗在乌国获批铺平了道路。
此外，ANSO秘书处的牵线也促进了该疫苗近期在巴基斯坦启动III期临床试验。对参与此疫苗合作的乌兹别克斯坦机构和个人，ANSO秘书处表示衷心的感谢。ANSO将继续发挥平台作用，促进国际科学技术合作，与更多国家和伙伴合作开发疫苗和药物，共克当前危机。
ANSO Facilitates the CAS-Developed Recombinant Protein COVID-19 Vaccine
to be on the Market in Uzbekistan
“I thank you, all ANSO and Zhifei leaders and the team for all your support and bridging this collaboration!!! We come up to this level because of great teamwork and friendship. I believe that this is the beginning and the best yet to come!”
--- Mr. Ibrokhim Abdurakhmonov, the Minister of Innovation and Development of the Republic of Uzbekistan
On March 2nd, the Ministry of Innovative Development of Uzbekistan has certified a COVID-19 vaccine (registered as “ZF-UZ-VAC2001”) developed by Chinese Academy of Sciences (CAS) and produced by China's Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. Uzbekistan has registered it for emergency use and marketing authorization.
ANSO has played a crucial bridging role in this process. From August of 2020, ANSO Secretariat has promoted and organized over 20 online workshops on implementing the Phase III Clinical Trial by working together with scientists, pharmacists and government officials from CAS, Zhifei Longcom as well as their counterparts from Uzbekistan, Chile, Philippines, Brazil, South Africa, Ghana, Senegal, Sir-Lanka, Pakistan, and so forth.
Thanks to strong support from the Ministry of Innovation and Development of Uzbekistan, the Phase III Clinical Trial of the said vaccine was started in December 2020. The results for over 7000 subjects showed good safety and high efficacy (scientific outcomes to be published soon), which led to the registration for emergency use and marketing authorization.
In addition, ANSO also coordinated with Pakistan Academy of Sciences to promote the trial cooperation in Pakistan which will be carried out in the near future.
We owe our gratitude to the officials, scientists and numerous individuals in Uzbekistan for their great efforts in the matter. Paving the way for a post-pandemic world, ANSO is keen to involve more actively in tackling global challenges through joint actions on science, technology, innovation and capacity building. We look forward to working with more members, partners and countries to overcome the current pandemic.